TapImmune (NSDQ:TPIV) expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform. Details regarding merger-related financing were not disclosed, but TapImmune said it is in talks with a syndicate of institutional investors to fund the company until 2020. “I believe that the new therapies we are […]
tapimmune
TapImmune brings therapeutic vaccines into the clinic for ovarian, breast cancer
In the past decade, new innovations and well-funded research have heralded in the era of immunotherapy. The pace of change within the field has amazed Peter Hoang, the chief executive of a Jacksonville, Fl.-based company working to develop therapeutic vaccines for cancer. “15 years ago, if you or I walked into a venture capitalist’s office, […]
